Find Experts

Experts in Haematology
Julio A Aguirre-Ghiso Alberto Toso Yan Xiaojing William G. Finn Afua Mensah Scott A. Armstrong Richard Oscar Francis Jose Javier Bravo Cordero Steven J Burakoff Arek Z. Dudek Balkrishna Jahagirdar Dan J. Schneider Dr. David Saunders Bamlaku Enawgaw Dylan Zylla Muhammad Yasin Tipu Mr. Máté SZILASSY Mr. Roberto MARCOS Mr. Brian CONIBERE Mr. Julio FREYRE View More
Ryan Cassaday

Assistant Professor
Hematology
Fred Hutchinson Cancer Rearch Center
United States of America

Professor Haematology
Biography

Dr. Cassaday is an assistant professor of medicine who specializes in the care of patients with blood cancers, specifically leukemia and lymphoma. In addition to seeing patients at UWMC and SCCA, he studies new treatments for patients with acute lymphoblastic leukemia and aggressive lymphomas. Before he came to UW for a hematology/oncology fellowship, all of his prior education and training was at the University of Wisconsin in Madison. Dr. Cassaday joined the UW faculty right after completing his training. He is board certified in internal medicine, hematology and medical oncology.

Research Intrest

Developing novel therapies and risk-stratification methods for adults with acute lymphoblastic leukemia Radioimmunotherapy-based conditioning regimens for hematopoietic cell transplantation in adults with high-risk lymphoma

List of Publications
Landsburg, D. J., Falkiewicz, M. K., Maly, J., Blum, K. A., Howlett, C., Feldman, T., ... & Torka, P. (2017). Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of Clinical Oncology, JCO-2017.
Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Stelljes, M., Kebriaei, P., Cassaday, R. D., ... & Ejduk, A. A. (2017). Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. The Lancet Haematology.
Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., ... & Mukherjee, S. (2017). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. Leukemia & Lymphoma, 1-9.
Reddy, P., Kanan, S., Cowan, A., Warren, H., Till, B., Shadman, M., ... & Smith, S. D. (2017). Peg-GCSF Can be Used with First-Line (da)-EPOCH-R without Compromising Dose Intensity, Safety, or Efficacy. Clinical Lymphoma Myeloma and Leukemia.
Experts in United States of America
Jairaj K. Acharya John Belote Wayde Brown Aimée M. Dudley Jon P Mochel Rabaa M. Al-Rousan Chancellor, Renate Karen Lee Abt Lin Li Hui-Hsien Chou Hamed I. Aly Cory K. Adams Mark Ehrensberger Jose Buitrago Gerhard J. Barone Jacquelyne Adams Jon Calabria Shelley Cannady Susan B. Adams Stoica George Daniel E. Acuna Tal Amasay Jason R. Wiles Matthew H Andersen Brian Rothman View More